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Objective. The endothelial damage of microvascu-
lar structures in systemic sclerosis (SSc; scleroderma)
is associated with increased levels of endothelial adhe-
sion molecules and endothelium-associated cytokines,
including E-selectin and thrombomodulin. Although
there is still no ideal specific pharmacologic therapy for
SSc, cyclophosphamide has resulted in clinical improve-
ment in patients with SSc-related active alveolitis. This
study was designed to assess the expression of E-selectin
and thrombomodulin in patients with early diffuse SSc,
and to investigate the effects of oral cyclophosphamide
combined with prednisolone therapy on the levels of
these endothelium-associated cytokines and on the pa-
tients’ clinical outcomes.
Methods. Thirteen patients with early diffuse SSc
were treated with oral cyclophosphamide (2–2.5 mg/kg/
day) and methylprednisolone (30 mg/every other day)
for 1 year. The outcomes were determined as clinical
(skin score) and laboratory parameters (including the
erythrocyte sedimentation rate, complete blood cell
count, levels of C-reactive protein, antinuclear antibody,
anti–double-stranded DNA, rate of creatinine clearance,
and findings on pulmonary function tests, esophageal
manometry, and echocardiography). The concentra-
tions of E-selectin and thrombomodulin were measured
in the pretreatment and posttreatment serum samples
from the SSc patients and from 12 healthy adults as
controls.
Results. In the patients with early diffuse SSc,
pretreatment and posttreatment mean levels of
E-selectin were 51 ng/ml (range 34.2–135.5) and 33.4
ng/ml (range 23–62.5), respectively (P  0.01), and
those of thrombomodulin were 82 ng/ml (range 35.8–
120.5) and 74.6 ng/ml (range 23.3–91.3), respectively (P
 0.016). Clinical and laboratory parameters (the skin
score and measures of pulmonary function [forced vital
capacity and diffusing capacity for carbon monoxide])
were also improved (P < 0.05 for each) at the end of the
followup period.
Conclusion. Combination therapy with cylophos-
phamide plus prednisolone is effective in the treatment
of early diffuse SSc. Circulating levels of E-selectin and
thrombomodulin not only demonstrate the extent of
endothelial injury and/or activation, but also could be a
useful marker to monitor the disease activity in SSc.
Systemic sclerosis (SSc; scleroderma) is a sys-
temic autoimmune inflammatory connective tissue dis-
order that is characterized by excessive production of
extracellular matrix by fibroblasts as well as damage of
the endothelium of small vessels with subsequent intimal
hyperplasia and tissue ischemia, together with activation
of the immune system. Endothelial cell damage and
platelet activation can occur and may concurrently con-
tribute to the peripheral ischemia of the disease. In-
volvement of organs such as the lung, heart, kidney, gut,
and skin causes substantial morbidity and mortality in
SSc.
Vascular dysfunction is a key pathobiologic ele-
ment of the SSc disease process. Since vascular lesions
occur early in the course of the disease and precede the
development of fibrosis, endothelial cells have been
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implicated in the pathophysiology of fibrosis. Endothe-
lial cell damage is evident in SSc by the occurrence of
capillary drop-out and vascular leakage, leading to for-
mation of edema. Inflammatory cells are attracted to
damaged sites and migrate to adjacent tissue. In turn,
activated endothelial cells up-regulate the expression of
cytokines (1).
Adherence and extravasation of immunocompe-
tent cells depend on their interactions with adhesion
molecules. One of the best-characterized endothelial
cell adhesion molecules is E-selectin, which is mainly
restricted to activated endothelium (2,3). Thrombo-
modulin is a vascular endothelial surface glycoprotein
that is present on the luminal surface of endothelial
cells. Soluble thrombomodulin reflects the injury to the
endothelial cells, since the fragments of thrombomodu-
lin detected in the blood were not secreted by endothe-
lial cells under physiologic conditions (4). These endo-
thelial parameters thus might provide a useful tool for
the characterization and prediction of the activity and
progression of the disease (5).
Currently, there is no ideal and specific pharma-
cologic curative approach for scleroderma. However, the
therapeutic approach should be initiated at the early
stages of SSc, before the fibrosis begins to develop. In
interstitial lung disease, treatment with cyclo-
phosphamide in SSc may improve the inflammatory
aspects of the disease that occur before the development
of severe fibrosis, although this approach is still in the
experimental stages (6).
The aim of this study was to investigate the
efficacy and the toxicity of oral cyclophosphamide and
prednisolone therapy at the early stages of the disease,
by examining clinical outcomes (clinical and laboratory
findings) together with the levels of E-selectin and
thrombomodulin, which serve as the activation markers
of endothelial function.
PATIENTS AND METHODS
Patient selection and clinical evaluation. Thirteen
patients with early diffuse scleroderma (11 female, 2 male;
mean  SD age 37.8  11.3 years) were involved in this
prospective, open trial between 1996 and 1999. The disease
duration was 2 years in all patients, and all fulfilled the
criteria for SSc proposed by the American College of Rheu-
matology (formerly, the American Rheumatism Association)
(7). The initial symptoms of the patients were Raynaud’s
phenomenon, diffuse swelling of the hands, skin thickening,
esophageal symptoms (dysphagia, heartburn, or dyspnea), and
arthralgia. None of the patients was previously treated with
disease-modifying antirheumatic drugs. All of them had diffuse
cutaneous involvement, which is described as skin thickening
proximal to the elbow and/or knee, with or without face and
neck involvement (7). Patients who had severe pulmonary
involvement (forced vital capacity [FVC] 50% of predicted,
diffusing capacity for carbon monoxide [DLCO] 40% of
predicted) and comorbidities such as congestive heart failure,
chronic obstructive lung disease, or diabetes mellitus were
excluded from the study. Patients who were receiving aspirin or
any other nonsteroidal antiinflammatory drug that could affect
endothelial cell functions were not enrolled in the study.
Physical examinations of all patients were performed
by the same physician (ZO). The degree and the extent of the
dermal thickening were measured by using the semiquantita-
tive Rodnan skin scoring system (maximum score 104) (8).
Laboratory assessments comprised the erythrocyte sedimenta-
tion rate (ESR), complete blood cell (CBC) count, serum
biochemistry, C-reactive protein, rheumatoid factor, 24-hour
urinary microprotein excretion, creatinine clearance, urine
analysis, and immunologic parameters, including antinuclear
(ANA), anti–double-stranded DNA, anti–Scl-70 (topoisomer-
ase I), and anticentromere antibodies. Chest roentgenograms
were obtained, and electrocardiography, echocardiography,
esophagography, and pulmonary function tests (spirometry for
the DLCO) were also performed to evaluate organ involve-
ment. All of those parameters were evaluated by comparing
the results at the start and the end of the study.
As mentioned, pulmonary involvement was evaluated
by spirometry for measurement of the DLCO. An FVC 80%
of predicted, a forced expiratory volume in 1 second (FEV1)/
FVC 70% of predicted, and DLCO 80% of predicted were
defined as normal pulmonary function. The measured FVC
values 80% of predicted and FEV1/FVC 70% of predicted
were accepted as the predictors of restrictive pulmonary
disorders (9).
The above-mentioned clinical and laboratory para-
meters were reevaluated every 6 months up to 1 year. Serum
levels of thrombomodulin and E-selectin were determined at
the beginning and at the end of the study. Twelve healthy
volunteers (4 female, 8 male; mean  SD age 33.1  10.9
years) were accepted as the control group to compare the
levels of E-selectin and thrombomodulin.
Treatment schedule. All patients were treated with
2–2.5 mg/kg/day oral cyclophosphamide and with 30 mg/every
other day (equivalent to 15 mg/day) oral methylprednisolone.
The corticosteroid dose was tapered by 2.5 mg every 6 weeks
until reaching a dose of 2.5 mg/every other day, which was then
maintained.
Dose modification. Patients were followed up closely
for the expected side effects of the drugs. The CBC count and
urine analyses were repeated every 2 weeks. Development of
leukopenia (white blood cell [WBC] counts 3,500/mm3),
serious gastrointestinal intolerance, hematuria (5 red blood
cells/high-power field), and/or proteinuria (higher than 500
mg/day) was considered to be a definitive reason to withhold
cyclophosphamide. If minor side effects such as a decreased
WBC count between 3,500/mm3 and 5,000/mm3 or gastric
irritability developed, then temporary suspension of the cyclo-
phosphamide or a reduction in the dose to half for 1–2 weeks
was considered necessary. After the WBC count recovered, the
drug was continued at the initial dosage schedule.
Collection of serum samples. For measurement of the
levels of E-selectin and thrombomodulin, all serum samples
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were obtained between 9:00 and 10:00 in the morning from
resting subjects who had been required to fast. Care was taken
to avoid platelet activation, by the use of atraumatic needle
punctures, a butterfly needle, and minimal stasis with tourni-
quet release before blood withdrawal into 10-ml syringes.
Smokers were asked to abstain from smoking since the previ-
ous night (as of 12:00 midnight). Plasma was prepared for
measurement of thrombomodulin by collecting blood into
3.13% trisodium citrate, which was then centrifuged within 20
minutes of venipuncture at 3,000g. All samples for measure-
ment of thrombomodulin were stored at 80°C until assayed.
Blood samples for measurement of E-selectin were centrifuged
at 3,000g for 10 minutes, and aliquots of serum were stored at
30°C until assayed.
Measurement of E-selectin and thrombomodulin.
Thrombomodulin was measured with a microenzyme immu-
noassay technique using commercial kits (thrombomodulin
immunoassay; Diagnostica Stago, Asniéres-sur-Seine, France).
Circulating E-selectin was measured with a quantitative sand-
wich enzyme immunoassay technique using commercially
available assays (R&D Systems, Oxford, UK) in accordance
with the manufacturer’s instructions.
Statistical analysis. All data at the end of the first year
were collected and analyzed by using SPSS software, version
7.0 (SPSS, Chicago, IL). The pre- and posttreatment labora-
tory values of the cyclophosphamide group were compared by
the paired-sample t-test, and pre- and posttreatment clinical
values and E-selectin and thrombomodulin levels from the
cyclophosphamide group were compared by using the Wil-
coxon test. The comparison of the pretreatment E-selectin and
thrombomodulin levels in the patients and the healthy controls
was made by using the Mann-Whitney U test. A P value below
0.05 was considered statistically significant.
RESULTS
During the study period, 2 patients were excluded
from the treatment group because of lack of coopera-
tion. Their clinical and laboratory results were obtained
at entry, but they did not comply with the given time
schedule of visits. Thus, their results were not entered in
the statistical analysis. The results of the remaining 11
patients were evaluated. Pretreatment demographic fea-
tures of the patients, including age, sex distribution,
mean disease duration, skin involvement, evidence of
Raynaud’s phenomenon, joint involvement, pulmonary
involvement, and esophageal involvement, and ANA
and anti–topoisomerase I positivity are shown in Table
1. The patients’ clinical and laboratory findings before
and after treatment are shown in Table 2.
The therapeutic regimen of oral cyclo-
phosphamide and prednisolone at the given doses was
well tolerated by all patients. The most common side
effects appeared to be leukopenia and microscopic
hematuria. Most of the side effects were readily man-
Table 1. The clinical and demographic features of the systemic
sclerosis patients*
Feature Value
Age, years, mean  SD 37.8  11.3
Sex, no. female/no. male (% female) 9/2 (82)
Disease duration, months, mean  SD 11.8  7.1
Followup duration, months, mean  SD 16.7  4.1
Raynaud’s phenomenon 9 (81.8)
Joint involvement 5 (45.5)
Puffy hands 5 (45.5)
Nail-fold capillary dilatation 9 (81.8)
Pulmonary involvement 9 (81.8)
Esophageal involvement 6 (54.5)
Telangiectasia 1 (9.1)
Antinuclear antibody 9 (81.8)
Anti–Scl-70 antibody 8 (72.7)
* Except where otherwise indicated, values are the no. (%) of patients.
Table 2. Clinical and laboratory changes in the systemic sclerosis patients before (1) and after (2) cyclophosphamide and prednisolone therapy*
Patient
ESR CRP CLcr FVC DLCO Skin WBC
E-selectin,
ng/ml
Thrombomodulin,
ng/ml
1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
1 52 10 1.8 0.0 80 78 70 85 56 75 52 24 6,600 5,000 78.0 60.0 120.5 90.1
2 49 16 2.6 0.0 60 108 88 94 93 113 43 31 9,000 6,500 34.3 30.0 103.5 102.5
3 30 11 0.9 0.0 105 150 87 101 70 80 49 32 8,900 7,000 63.5 50.0 110.8 85.5
4 90 7 1.5 0.0 70 155 85 107 67 84 31 24 10,700 4,800 51.0 23.0 90.2 84.2
5 62 9 0.8 1.1 113 137 65 77 59 75 59 63 14,800 8,300 38.1 33.4 82.0 91.3
6 78 36 2.7 1.3 62 75 57 67 52 57 30 28 8,200 7,600 70.5 34.5 45.5 38.7
7 28 15 1.0 0.8 90 95 67 82 49 63 75 67 6,000 6,800 135.5 40.7 67.3 58.2
8 90 29 0.0 0.0 70 110 77 79 70 74 49 35 5,500 3,200 48.1 31.5 72.5 74.6
9 38 18 3.0 5.0 67 70 83 80 80 86 27 30 4,800 4,500 49.4 24.8 35.8 37.2
10 27 6 0.4 0.0 78 79 78 91 57 66 48 33 6,000 6,800 34.9 32.2 47.5 31.3
11 32 33 0.9 0.0 57 78 84 86 55 67 47 39 11,400 8,700 54.0 62.5 99.2 85.5
* ESR  erythrocyte sedimentation rate (mm/hour); CRP  C-reactive protein (mg/dl); CLcr  creatinine clearance (ml/minute); FVC  forced
vital capacity (% of predicted); DLCO  diffusing capacity for carbon monoxide (% of predicted); Skin  Rodnan’s skin score (maximum 104);
WBC  white blood cell count (cells/mm3).
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ageable by dose reduction. None of the toxic effects
necessitated complete cessation of the therapy. Skin
scores improved in most of the patients after cyclo-
phosphamide therapy (P  0.05). Moreover, the ESR
and WBC count were significantly decreased (P  0.05)
and the rate of creatinine clearance as well as the FVC
and DLCO values were significantly increased (P  0.05
for each) in the patients after the therapy (Table 3).
The median E-selectin level in the patient group
prior to treatment and in the control group was 51 ng/ml
(range 34.2–135.5) and 33.5 ng/ml (range 16.6–62.6),
respectively (P  0.01). The pretreatment thrombo-
modulin level was 82 ng/ml (range 35.8–120.5) in the
study group and was 36.8 ng/ml (range 30.7–44.5) in the
healthy controls (P  0.01). After the administration of
the cyclophosphamide and prednisolone therapy, the
E-selectin and thrombomodulin levels in the patients
with early diffuse SSc were significantly reduced (P 
0.01 and P  0.016 for E-selectin and thrombomodulin,
respectively) (Table 4).
DISCUSSION
In this study, the levels of E-selectin and throm-
bomodulin in patients at the early stages of scleroderma
were significantly elevated, indicating endothelial activa-
tion and/or injury in SSc. The most important observa-
tion in this study is that daily oral cyclophosphamide
therapy positively affects circulating endothelial cell
markers in SSc. To our knowledge, this is the first study
demonstrating a reduction in the overexpressed in vivo
E-selectin and thrombomodulin molecules after cyclo-
phosphamide treatment in patients with SSc.
Increased levels of E-selectin in the tissue and
circulating blood of SSc patients indicate that endothe-
lial cell activation and leukocyte adhesion take place in
the pathobiology of the disease (2,10,11–23). SSc fibro-
blasts promote leukocyte migration across endothelial
cell monolayers (24). Other adhesive molecules could
also complicate the pathologically altered endothelial
cell functions in SSc (25–34). The increased soluble
thrombomodulin concentration indicates endothelial in-
jury in vasculitides (21,35,36).
In previous studies, iloprost decreased thrombo-
modulin levels but nifedipine did not (22), and cyclo-
sporine treatment affected the expression of adhesion
molecules (37) in scleroderma. Cyclophosphamide sup-
presses lymphokine production and modulates lympho-
cyte functions by alkylating various cellular constituents,
and depresses the inflammatory response via normaliza-
tion of neutrophilia and healing of vascular endothelial
cells. Cyclophosphamide could be effective in the early
inflammation stage of SSc lung involvement, before
fibrosis has developed. Nevertheless, high-dose cortico-
steroid therapy alone has also been shown to be effica-
cious in some cases of scleroderma, especially in those
with neutrophilic alveolitis (38). Active interstitial lung
disease could be improved after the use of oral cyclo-
phosphamide and low-dose prednisolone (39). Further-
more, cyclophosphamide plus prednisolone combination
therapy has considerably improved the effect on both
cutaneous involvement and pulmonary fibrosis (40,41).
Later observations confirmed the efficacy of this combi-
nation therapy on pulmonary SSc (42).
In our study, treatment of patients with early
diffuse SSc with oral cyclophosphamide, before visceral
Table 3. Comparison of pretreatment and posttreatment clinical and
laboratory parameters of the systemic sclerosis patients*
Parameter Pretreatment Posttreatment P
Skin score, median (range) 48 (27–75) 32 (24–67) 0.007
ESR, mm/hour 52.3  24.4 17.2  10.6 0.02
WBC, mm3 8,300  3,037 6,290  1,710 0.02
Creatinine clearance,
ml/minute
77.4  18.3 103.1  31.4 0.009
FVC, mean % of predicted 76.4  10.3 86.2  11.3 0.001
DLCO, mean % of predicted 64.3  13.2 76.3  15 0.001
* Except where otherwise indicated, values are the mean  SD. See
Table 2 for definitions.
Table 4. The elevation of thrombomodulin and E-selectin levels in comparison with healthy controls,
and their decrease after cyclophosphamide and prednisolone therapy in patients with systemic sclerosis*
Control
Patients
P† P‡Pretreatment Posttreatment
Thrombomodulin, ng/ml 36.8 (30.7–44.5) 82 (35.8–120.5) 74.6 (23.3–91.3) 0.001 0.016
E-selectin, ng/ml 33.5 (16.6–62.6) 51 (34.2–135.5) 33.4 (23–62.5) 0.008 0.01
* Except where otherwise indicated, values are the median (range).
† The comparison of baseline levels between the patients and the healthy controls, by Mann-Whitney U
test.
‡ The comparison between pretreatment and posttreatment levels in the patients, by Wilcoxon test.
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involvement, was approached on the basis of its mecha-
nism of action. Considering the side effects associated
with long-term high-dose corticosteroid therapy (40), we
preferred to use alternate-day oral steroid therapy in
relatively low doses and we tapered the steroid dose as
soon as possible. Daily oral cyclophosphamide plus
alternate-day oral prednisolone therapy was well toler-
ated in our SSc patients.
Interestingly, in our present study, we observed
that increased E-selectin levels returned to normal after
cyclophosphamide combination therapy in our SSc pa-
tients. Soluble thrombomodulin concentrations also sig-
nificantly improved; however, thrombomodulin levels
did not normalize in the SSc patients. Expression of
adhesion molecules, including E-selectin, on endothelial
cells is a dynamic, ongoing process in health and disease.
Up-regulation of selectins may actively contribute to the
increased adherence and extravasation of leukocytes.
Cyclophosphamide treatment seems to adjust that pro-
cess in SSc. In contrast, soluble thrombomodulin mole-
cules are heterogeneous fragments that mainly originate
from injured endothelial membranes. Therefore, circu-
lating thrombomodulin levels have been accepted as a
significant marker of endothelial damage and injury in
vasculitides (35,36). Because our SSc patients had a
damaged endothelium due to their disease, cyclo-
phosphamide combination therapy failed to produce a
completely normal endothelial structure, since the
thrombomodulin levels did not normalize. However, the
treatment did significantly improve endothelial function,
as demonstrated via decreased thrombomodulin and
normalized E-selectin concentrations in our patients.
Our findings represent the basis for larger, con-
trolled studies, which would elucidate the potential value
of endothelial molecules as surrogate markers for the
clinical progression or remission of SSc in relation to
distinct treatments. An effective approach to clinical
assessment of SSc patients might be developed if our
hypotheses are supported by further investigations in
that framework.
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